Published in Clin Vaccine Immunol on January 16, 2013
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J Biol Chem (2013) 0.90
Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother (2014) 0.88
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
Identification of toxemia in patients with Clostridium difficile infection. PLoS One (2015) 0.84
The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. PLoS One (2013) 0.82
Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther (2014) 0.81
An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol (2016) 0.80
A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model. Clin Vaccine Immunol (2015) 0.78
Study of the frequency of Clostridium difficile tcdA, tcdB, cdtA and cdtB genes in feces of Calves in south west of Iran. Ann Clin Microbiol Antimicrob (2014) 0.78
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs (2014) 0.75
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther (2016) 0.75
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci (2015) 0.75
Targeted FcγR mediated clearance by a biparatopic bispecific antibody. J Biol Chem (2017) 0.75
Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration. Clin Exp Immunol (2017) 0.75
High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection. Clin Exp Gastroenterol (2017) 0.75
Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiol (2017) 0.75
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Clostridium difficile infection in Europe: a hospital-based survey. Lancet (2011) 6.25
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol (2007) 4.09
Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog (2012) 3.81
Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. J Exp Med (1971) 3.51
Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet (1998) 3.29
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun (2011) 2.87
Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol (2009) 2.62
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest (2006) 2.16
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology (2003) 1.91
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun (2001) 1.85
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62
Intestinal uptake of macromolecules. II. Effect of parenteral immunization. J Immunol (1973) 1.53
Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 1.47
A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun (2007) 1.46
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest (1997) 1.39
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med (2010) 1.36
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ (2011) 1.31
Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. Infect Immun (1984) 1.28
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med (2007) 1.24
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol (1997) 1.20
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Immunological control mechanism against cholera toxin: interference with toxin binding to intestinal receptors. Infect Immun (1976) 1.17
Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis (2004) 1.16
A study of in vivo immune complex formation and clearance in man. J Immunol (1990) 1.14
Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol (1987) 1.12
Clostridium difficile and acute respiratory distress syndrome. Heart Lung (2004) 1.11
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother (2004) 1.09
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun (1989) 0.91
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun (2011) 0.89
The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine (2010) 0.87
Studies in cobra venom factor treated rats of antibody coated erythrocyte clearance by the spleen: differential influence of red blood cell antigen number on the inhibitory effects of immune complexes on Fc dependent clearance. Clin Exp Immunol (1986) 0.87
The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol (2012) 0.85
Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine (2005) 0.84
Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci (2012) 0.80
Synergistic interactions of antibodies in rate of virus neutralization. Virology (2000) 0.80
The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. Proc Natl Acad Sci U S A (2009) 2.69
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem (2002) 1.53
Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res (2003) 1.29
A processed noncoding RNA regulates an altruistic bacterial antiviral system. Nat Struct Mol Biol (2011) 1.24
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest (2008) 1.09
A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res (2009) 1.08
Selective ablation of retinoblastoma protein function by the RET finger protein. Mol Cell (2005) 1.05
Lipoyl synthase inserts sulfur atoms into an octanoyl substrate in a stepwise manner. Angew Chem Int Ed Engl (2006) 1.02
Bold coloration and the evolution of aposematism in terrestrial carnivores. Evolution (2011) 0.99
Product inhibition in the radical S-adenosylmethionine family. FEBS Lett (2009) 0.95
Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability. J Biol Chem (2012) 0.89
Effects of daily stressors on the psychological and biological well-being of spouses of persons with mild cognitive impairment. J Gerontol B Psychol Sci Soc Sci (2011) 0.88
A CHO cell line engineered to express XBP1 and ERO1-Lα has increased levels of transient protein expression. Biotechnol Prog (2013) 0.88
Thiamine biosynthesis in Escherichia coli: isolation and initial characterisation of the ThiGH complex. FEBS Lett (2003) 0.88
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res (2003) 0.87
Optimized conjugation of a fluorescent label to proteins via intein-mediated activation and ligation. Bioconjug Chem (2004) 0.86
The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol (2012) 0.85
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem Lett (2006) 0.84
PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem (2003) 0.84
Impact of discontinued obstetrical services in rural Missouri: 1990-2002. J Rural Health (2008) 0.84
Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki coupling. Org Lett (2008) 0.84
Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci (2008) 0.82
Retinal hemorrhages in patients with epidural hematomas. J AAPOS (2008) 0.81
The activity of a thermostable lipoyl synthase from Sulfolobus solfataricus with a synthetic octanoyl substrate. Anal Biochem (2006) 0.81
Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos (2005) 0.81
Preparation of heteroaryloxetanes and heteroarylazetidines by use of a Minisci reaction. J Org Chem (2009) 0.81
Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel (2012) 0.81
Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci (2012) 0.80
A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes. Org Biomol Chem (2006) 0.77
Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett (2007) 0.77
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents. Bioorg Med Chem Lett (2013) 0.76
Pediatric cutaneous bleach burns. Child Abuse Negl (2013) 0.76
Prostaglandin F2alpha produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology (2005) 0.75
Potential impact of AUSFTA on Australia's blood supply. Med J Aust (2007) 0.75
Gender and the neighborhood location of mixed-race couples. Demography (2013) 0.75
Bilateral femoroacetabular impingement. Orthop Nurs (2011) 0.75
An 18-month-old boy with severe dermatitis, edema, muscle wasting. Pediatr Ann (2011) 0.75
Introduction of a routine quan/qual approach into research DMPK: experiences and evolving strategies. Bioanalysis (2014) 0.75
Stereochemical analysis of methorphan using (-)-menthyl chloroformate. J Forensic Sci (2012) 0.75
Degradation in soil of precursors and by-products associated with the illicit manufacture of methylamphetamine: implications for clandestine drug laboratory investigation. Forensic Sci Int (2012) 0.75
Clinical inquiries. Does breastfeeding protect against viral GI infections in children <2 years old? J Fam Pract (2003) 0.75
Clinical inquiries. Should home apnea monitoring be recommended to prevent SIDS? J Fam Pract (2004) 0.75
The Influence of Intraoperative Testing on Surgical Decision-making During Cochlear Implantation. Otol Neurotol (2017) 0.75
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem (2010) 0.75
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat. Behav Pharmacol (2012) 0.75
Racial and ethnic disparities in physical abuse reporting and child protective services interventions in the United States. J Natl Med Assoc (2012) 0.75
Lisfranc fracture-dislocation. Orthop Nurs (2011) 0.75
Proximal tibia aneurysmal bone cyst. Orthop Nurs (2011) 0.75
Emotion categorization of facial expressions: Age differences in the utilization of diagnostic features. J Vis (2015) 0.75